3 assets in Pleomorphic Xanthoastrocytoma

Therapeutic assets addressing Pleomorphic Xanthoastrocytoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dabrafenib Pleomorphic Xanthoastrocytoma	Novartis Pharmaceuticals	P4	BB (65)
Trametinib Pleomorphic Xanthoastrocytoma	Novartis Pharmaceuticals	P4	BB (65)
Onc 206 Pleomorphic Xanthoastrocytoma	Jazz Pharmaceuticals	P1	CC (43)